ľ¹ÏÖ±²¥

Hospitals that participate actively and consistently in Get With The Guidelines^®- AFIB are eligible for public recognition.  Participating in GWTG-AFIB is the first level of recognition. It acknowledges program participation and entry of baseline data into the Registry Tool. 

Get With The Guidelines - AFIB Achievement Measures.

The different levels reflect the amount of time for which the hospital demonstrates performance at a minimum of 85% compliance.

• Bronze: recognizes performance of 90 consecutive days.
• Silver recognizes performance of 12 consecutive months.
• Gold recognizes performance of 24 consecutive months or more.
  
  Download Recognition Criteria for Get With The Guidelines - AFib

The Achievement Measures are embedded in the Registry Tool. They are:

• ACEI/ARB or ARNI Prescribed Prior to Discharge (When LVEF ≤40): Percentage of patients with a diagnosis of AF or atrial flutter, with HF with an LVEF ≤40, who were prescribed an ACEI, ARB or ARNI prior to discharge.
• CHA2DS2–VASc risk Score Documented Prior to Discharge: Percent of patients, age 18 and older, with nonvalvular and bioprosthetic valve Atrial Fibrillation or Atrial Flutter for in whom assessment of thromboembolic risk factors using the CHA2DS2- VASc risk score criteria has been documented in the medical record.
• Beta Blocker Prescribed Prior to Discharge (when LVEF ≤ 40): Percentage of patients, age ≥18 y, with a diagnosis of AF or atrial flutter with an LVEF ≤40 who were prescribed a beta blocker prior to discharge.
• FDA approved Anticoagulation Prescribed Prior to Discharge: Percent of patients, age 18 and older, with nonvalvular, valvular and bioprosthetic valve atrial fibrillation or atrial flutter who were discharged on warfarin or another Food and Drug Administration (FDA) approved other anticoagulant drug that is FDA approved for the prevention of thromboembolism for all patients with nonvalvular, valvular and bioprosthetic valve atrial fibrillation or atrial flutter at high risk for thromboembolism, according to CHA2DS2–VASc risk stratification.
• PT/INR Planned Follow-Up Documented Prior to Discharge for Warfarin Treatment: Percentage of patients, age ≥18 y, with nonvalvular, valvular and bioprosthetic valve AF or atrial flutter who have been prescribed warfarin and who have a PT/INR follow-up scheduled prior to hospital discharge.
• Statin at discharge in AF patients with CAD, CVA/TIA, PVD, or Diabetes: Percent of patients with either CAD, CVA/TIA, PVD or diabetes who were prescribed a statin at hospital discharge.
  
  

   We thank you for your continued dedication to improving patient care, if you have any questions please contact your local representative or email [email protected].

Please note: Recognition criteria are subject to change based on program enhancements